smegmatiscells were incubated for 3 h with and without ebselen (100 g/mL), followed by treatment with Tre-DNP-C8 Treatment and control as described above. to the mycobacterial cell surface. Phagocytosis of Tre-DNP-modifiedM. smegmatisby macrophages was significantly enhanced in the presence of anti-DNP antibodies, demonstrating proof-of-concept that our strategy can augment the sponsor immune response. Because the metabolic pathways responsible for cell surface incorporation of Tre-DNPs are conserved in all Mycobacteriales organisms but absent from additional bacteria and humans, the reported tools may be enlisted to interrogate host-pathogen relationships and develop immune-targeting strategies for varied mycobacterial pathogens. == Graphical Abstract == == Intro == Mycobacterial pathogens are characterized by a distinctive dual-membrane cell envelope that provides extraordinary safety from antibiotics and is a major driver of acquired drug resistance. The most prominent Sarpogrelate hydrochloride example of these organisms isMycobacterium tuberculosis, which every year causes approximately 10 million instances of active tuberculosis (TB) and 1.6 million deaths, making it the worlds leading cause of death by a Sarpogrelate hydrochloride bacterial pathogen.1,2Due to intrinsic drug tolerance provided by the mycobacterial cell envelope, standard treatment ofM. tuberculosisinfections requires the administration of multiple medicines over the course of 6 months.3,4The long duration, intensiveness, and side effects associated with this treatment regimen curb its effectiveness and have ultimately contributed to the emergence of multi-drug resistant (MDR)-TB, which is extremely challenging and expensive to treat.4,5Other mycobacterial infections are similarly recalcitrant to treatment with antibiotics. Non-tuberculous mycobacteria (NTM), such asM. aviumandM. abscessus, are ubiquitous and represent an increasingly common cause of severe pulmonary disease, particularly in immunocompromised individuals (e.g., individuals with cystic fibrosis or HIV).6,7Treatment of NTM illness involves a complicated 12-month combinatorial drug regimen that is often ineffective and may lead to the acquisition of resistance mutations.8,9Leprosy, diphtheria, and Buruli ulcer, which are also caused by mycobacteria or closely related corynebacteria, also present challenges with respect to chemotherapy and drug resistance.10Given the inherent difficulty of treating mycobacterial infections with existing antibiotics, the rise and spread of strains with accumulated antibiotic resistance mutations, and the paucity of fresh anti-mycobacterial compounds in the drug pipeline, there is a need for novel therapeutic approaches that complement traditional antibiotics.11,12 Host-directed immunotherapies represent an attractive target for novel anti-mycobacterial treatments.1316A powerful cell-mediated immune response is needed to eliminateM. tuberculosisfrom their intracellular market within the macrophage, as well as to foster the development of interferon–producing T cells that preserve granuloma structure during latent tuberculosis.17Likewise, protective immune response to pulmonary NTM include macrophage killing and T cell-dependent cytokine production.18Given the well-established part of cellular effector functions, but despite evidence showing that antibodies are protective in most cases,19the potential part of antibodies in mycobacterial infections has been underappreciated until recently. To address whether antibodies played a protective part in mycobacterial infections, Watson and colleagues recently showed that a monoclonal antibody directed againstM. Sarpogrelate hydrochloride tuberculosisphosphate transporter subunit PstS1 improved mycobacterial uptake by a macrophage cell collection, decreased bacterial figures, and improved survival in mice.20Antibody ligation of Fc-receptors and subsequent Fc-receptor signaling is a likely driver of this protective response because antibody-targeting ofM. bovis, as well as other intracellular bacteria, to Fc-receptors raises lysosome fusion and restricts intracellular growth in phagocytes.2025Together, these data support the notion that antibodies, which target Sarpogrelate hydrochloride mycobacterial surface molecules and enhance phagocytosis, might be a successful immunotherapy. On the basis that Fc-mediated phagocytosis enhances phagocytosis and killing of additional intracellular pathogens,23,25we hypothesized that specific cell surface executive of mycobacterial glycans with antibody-recruiting small molecules (ARMs) would enhance antibody-dependent phagocytosis by macrophages. ARMs are rationally designed to contain a pathogen-targeting motif and an antibody recruitment motif, the second option of which is definitely identified by naturally happening antibodies to result in macrophage effector functions.2630In order to overcome developing drug resistance, as well as immune evasion caused by natural variation in surface antigens, the selection of the pathogen-targeting motif can also be personalized to select essential surface Rabbit Polyclonal to MYOM1 molecules where mutations would be lethal. The ARM concept offers previously been applied to generate immunotherapy strategies for tumor,3134viruses,35fungi,36and.